FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980187589> ?p ?o ?g. }

• W2980187589 endingPage "662" @default.
• W2980187589 startingPage "653" @default.
• W2980187589 abstract "Lymphocyte depletion has been shown to control costimulation blockade-resistant rejection but, in some settings, to exacerbate antibody-mediated rejection (AMR). We have used alemtuzumab, which depletes T and B cells, combined with belatacept and rapamycin and previously reported control of both costimulation blockade-resistant rejection and AMR. To evaluate this regimen’s effect on B cell signatures, we investigated 40 patients undergoing this therapy. B cell counts and phenotypes were interrogated using flow cytometry, and serum was analyzed for total IgG, IgM, and donor-specific alloantibody (DSA). Alemtuzumab induction produced pan-lymphocyte depletion; B cells repopulated faster and more completely than T cells. Reconstituting B cells were predominantly naïve, and memory B cells were significantly reduced (P = .001) post repopulation. Two B cell populations with potential immunomodulatory effects—regulatory (CD38hiCD24hiIgMhiCD20hi) and transitional B cells (CD19+CD27−IgD+CD38hi)—were enriched posttransplant (P = .001). Total serum IgG decreased from baseline (P = .016) while IgM levels remained stable. Five patients developed DSAs within 36 months posttransplant, but none developed AMR. Baseline IgG levels in these patients were significantly higher than those in patients without DSAs. These findings suggest that belatacept and rapamycin together limit homeostatic B cell activation following B cell depletion and may lessen the risk of AMR. This regimen warrants prospective, comparative study. ClinicalTrials.gov NCT00565773. Lymphocyte depletion has been shown to control costimulation blockade-resistant rejection but, in some settings, to exacerbate antibody-mediated rejection (AMR). We have used alemtuzumab, which depletes T and B cells, combined with belatacept and rapamycin and previously reported control of both costimulation blockade-resistant rejection and AMR. To evaluate this regimen’s effect on B cell signatures, we investigated 40 patients undergoing this therapy. B cell counts and phenotypes were interrogated using flow cytometry, and serum was analyzed for total IgG, IgM, and donor-specific alloantibody (DSA). Alemtuzumab induction produced pan-lymphocyte depletion; B cells repopulated faster and more completely than T cells. Reconstituting B cells were predominantly naïve, and memory B cells were significantly reduced (P = .001) post repopulation. Two B cell populations with potential immunomodulatory effects—regulatory (CD38hiCD24hiIgMhiCD20hi) and transitional B cells (CD19+CD27−IgD+CD38hi)—were enriched posttransplant (P = .001). Total serum IgG decreased from baseline (P = .016) while IgM levels remained stable. Five patients developed DSAs within 36 months posttransplant, but none developed AMR. Baseline IgG levels in these patients were significantly higher than those in patients without DSAs. These findings suggest that belatacept and rapamycin together limit homeostatic B cell activation following B cell depletion and may lessen the risk of AMR. This regimen warrants prospective, comparative study. ClinicalTrials.gov NCT00565773." @default.
• W2980187589 created "2019-10-18" @default.
• W2980187589 creator A5003258065 @default.
• W2980187589 creator A5029397195 @default.
• W2980187589 creator A5056389032 @default.
• W2980187589 creator A5057925324 @default.
• W2980187589 creator A5062504853 @default.
• W2980187589 creator A5073028134 @default.
• W2980187589 creator A5080679206 @default.
• W2980187589 date "2020-03-01" @default.
• W2980187589 modified "2023-10-11" @default.
• W2980187589 title "B cell reconstitution following alemtuzumab induction under a belatacept-based maintenance regimen" @default.
• W2980187589 cites W1554010547 @default.
• W2980187589 cites W1554670304 @default.
• W2980187589 cites W1606417387 @default.
• W2980187589 cites W1616440767 @default.
• W2980187589 cites W1862437987 @default.
• W2980187589 cites W1928653608 @default.
• W2980187589 cites W1946392463 @default.
• W2980187589 cites W1949819251 @default.
• W2980187589 cites W1951106665 @default.
• W2980187589 cites W1963701987 @default.
• W2980187589 cites W1975206040 @default.
• W2980187589 cites W1978045461 @default.
• W2980187589 cites W1988034903 @default.
• W2980187589 cites W2001172799 @default.
• W2980187589 cites W2006236831 @default.
• W2980187589 cites W2010606148 @default.
• W2980187589 cites W2040186210 @default.
• W2980187589 cites W2042021216 @default.
• W2980187589 cites W2076628707 @default.
• W2980187589 cites W2077355017 @default.
• W2980187589 cites W2077684987 @default.
• W2980187589 cites W2080773387 @default.
• W2980187589 cites W2081695157 @default.
• W2980187589 cites W2086703018 @default.
• W2980187589 cites W2088328410 @default.
• W2980187589 cites W2089774344 @default.
• W2980187589 cites W2099785704 @default.
• W2980187589 cites W2099868898 @default.
• W2980187589 cites W2104170524 @default.
• W2980187589 cites W2107346812 @default.
• W2980187589 cites W2107455390 @default.
• W2980187589 cites W2109780539 @default.
• W2980187589 cites W2132182183 @default.
• W2980187589 cites W2134672034 @default.
• W2980187589 cites W2137442990 @default.
• W2980187589 cites W2143041251 @default.
• W2980187589 cites W2146104890 @default.
• W2980187589 cites W2158109599 @default.
• W2980187589 cites W2159873875 @default.
• W2980187589 cites W2219468584 @default.
• W2980187589 cites W2273711624 @default.
• W2980187589 cites W2301588580 @default.
• W2980187589 cites W2317185835 @default.
• W2980187589 cites W2418706972 @default.
• W2980187589 cites W2469244910 @default.
• W2980187589 cites W2544264923 @default.
• W2980187589 cites W2613714577 @default.
• W2980187589 doi "https://doi.org/10.1111/ajt.15639" @default.
• W2980187589 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7202689" @default.
• W2980187589 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31596034" @default.
• W2980187589 hasPublicationYear "2020" @default.
• W2980187589 type Work @default.
• W2980187589 sameAs 2980187589 @default.
• W2980187589 citedByCount "8" @default.
• W2980187589 countsByYear W29801875892020 @default.
• W2980187589 countsByYear W29801875892021 @default.
• W2980187589 crossrefType "journal-article" @default.
• W2980187589 hasAuthorship W2980187589A5003258065 @default.
• W2980187589 hasAuthorship W2980187589A5029397195 @default.
• W2980187589 hasAuthorship W2980187589A5056389032 @default.
• W2980187589 hasAuthorship W2980187589A5057925324 @default.
• W2980187589 hasAuthorship W2980187589A5062504853 @default.
• W2980187589 hasAuthorship W2980187589A5073028134 @default.
• W2980187589 hasAuthorship W2980187589A5080679206 @default.
• W2980187589 hasBestOaLocation W29801875891 @default.
• W2980187589 hasConcept C126322002 @default.
• W2980187589 hasConcept C159654299 @default.
• W2980187589 hasConcept C203014093 @default.
• W2980187589 hasConcept C2778453870 @default.
• W2980187589 hasConcept C2778957590 @default.
• W2980187589 hasConcept C2779015954 @default.
• W2980187589 hasConcept C2780303639 @default.
• W2980187589 hasConcept C2780743877 @default.
• W2980187589 hasConcept C2781413609 @default.
• W2980187589 hasConcept C2911091166 @default.
• W2980187589 hasConcept C2994498544 @default.
• W2980187589 hasConcept C48010095 @default.
• W2980187589 hasConcept C71924100 @default.
• W2980187589 hasConceptScore W2980187589C126322002 @default.
• W2980187589 hasConceptScore W2980187589C159654299 @default.
• W2980187589 hasConceptScore W2980187589C203014093 @default.
• W2980187589 hasConceptScore W2980187589C2778453870 @default.
• W2980187589 hasConceptScore W2980187589C2778957590 @default.
• W2980187589 hasConceptScore W2980187589C2779015954 @default.
• W2980187589 hasConceptScore W2980187589C2780303639 @default.
• W2980187589 hasConceptScore W2980187589C2780743877 @default.

• next